Lee County child tests negative for measles, says Alabama Department of Public Health
Dr. Scott Harris, state health officer at Alabama Department of Public Health, speaks to the State Committee of Public Health meeting on April 10, 2025, in Montgomery. Harris told the committee on Thursday that a Lee County child suspected of having measles tested negative for the disease. (Alander Rocha/Alabama Reflector)
Alabama's state health officer said Thursday that a suspected measles case in Lee County turned out to be negative, meaning the state has not yet seen a confirmed case of the disease this year amid measles outbreaks around the nation.
Dr. Scott Harris Thursday told the State Committee of Public Health, which oversees the Alabama Department of Public Health, that the suspected case was in a child just under 12 months old who was not yet eligible for the measles, mumps, and rubella (MMR) vaccine. The child had symptoms such as fever and rash, but tested negative on Wednesday.
'At this point, we don't have our first measles case from this outbreak, that we know of anyway,' Harris said.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
ADPH reported Sunday it was investigating a suspected case of measles. In March, the department investigated a possible measles exposure after an unvaccinated child who traveled through the state later tested positive for measles.
Alabama's MMR vaccination rate among kindergartners was 93.8% in the 2023-2024 school year, under the 95% rate set by the U.S. Centers for Disease Control and Prevention (CDC) to achieve herd immunity.
Harris has said in each board meeting since the outbreaks started this year that a case in Alabama 'is coming.' He said there could still be undetected cases, especially in areas with low vaccination rates, that can lead to an outbreak.
'If you have a case that reaches some population, for example, a day care, where kids aren't old enough to be vaccinated yet. You could expose dozens of children at once,' Harris said after the board meeting.
An outbreak that started with two unvaccinated school-age children in west Texas in January has now spread to at least 33 other states, according to the Centers for Disease Control and Prevention (CDC). Since the first outbreak this year, authorities have reported nearly 1,200 cases in people who are either unvaccinated or have unknown status. Of total cases, 12% have been hospitalized and three people have died.
The measles vaccine has significantly reduced severe illness and fatalities since it became available in 1973; previously, measles led to an estimated 48,000 hospitalizations and 400-500 deaths annually in the U.S. Two doses of the MMR vaccine are 97% effective at preventing measles, and one dose is 93% effective.
Through April, the MMR vaccination rate in Texas was up 450%, compared to its vaccination rate in 2019, according to The Texas Tribune. Since the outbreak, Texas health officials have made the vaccine, which is typically available to children ages one and older, available to infants older than six months. Health officials have also attributed the increased vaccine uptake to public awareness.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
an hour ago
- CBS News
New COVID variant NB.1.8.1 could be more than 1 in 3 cases, CDC projects
What to know about changes in CDC guidance for COVID-19 vaccine The new COVID-19 variant NB.1.8.1, which was linked to a large surge of hospitalizations in parts of Asia, could now make up more than 1 in 3 cases across the United States, the Centers for Disease Control and Prevention projected this week. Last month, the CDC's airport surveillance program had detected cases of the variant in arriving international travelers from several countries. The agency now says that nearly half of the COVID infections detected in that program the last week of May were the NB.1.8.1 variant. The CDC cautioned that "precision in the most recent reporting period is low" for their estimates, meaning the projections carry a wide margin of error. Still, the estimated increase in prevalence in the U.S. highlights the variant's high transmissibility — something experts had warned about as soon as it began spreading in this country. "Data indicates that NB.1.8.1 does not lead to more severe illness compared to previous variants, although it appears to have a growth advantage, suggesting it may spread more easily. In other words, it is more transmissible," Subhash Verma, a professor of microbiology and immunology at the University of Nevada, Reno School of Medicine, previously told CBS News. Symptoms of the variant are broadly similar to those seen in earlier strains, Verma noted. Typical symptoms include respiratory issues such as cough and sore throat, as well as systemic issues like fever and fatigue. As health officials continue monitoring the virus, the Trump administration has recently made moves to change access to vaccines for some Americans. In May, the Food and Drug Administration said it will continue approving COVID-19 vaccine updates for seniors and those with an underlying medical condition, including pregnancy or diabetes, but will require vaccine makers to conduct major new clinical trials before approving them for wider use. The decision means many people without underlying conditions may not have access to updated shots this fall. Health and Human Services Secretary Robert F. Kennedy Jr. also said last month that he would remove the CDC's recommendation for children and healthy pregnant women to get vaccinated against COVID-19. Later that week, however, the CDC said that kids with no underlying health conditions "may receive" COVID-19 vaccines. "Where the parent presents with a desire for their child to be vaccinated, children 6 months and older may receive COVID-19 vaccination, informed by the clinical judgment of a healthcare provider and personal preference and circumstances," the CDC says in its new guidance. contributed to this report.

an hour ago
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease. Previously, the vaccine, known as mRESVIA, had been licensed for use for those aged 60 and older. Approval for mRESVIA came after Moderna conducted a late-stage clinical trial showing the vaccine helped boost immune responses in younger adults. More than one-third of adults between ages 18 and 59 have at least one underlying condition that puts them at increased risk of RSV, according to Moderna. "RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV," Stéphane Bancel, CEO of Moderna, said in a press release. "We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV." Although the FDA approves vaccines and may expand approvals for certain age groups, the Centers for Disease Control and Prevention sets recommendations regarding who should get vaccines and when. Currently, the CDC recommends RSV vaccination only for those aged 75 and older and for those aged 60 and over at increased risk. The CDC's independent vaccine advisory committee will need to vote to recommend that the new age group be eligible for the shot, followed by a final recommendation from the director of the CDC. Earlier this week, Kennedy removed all 17 sitting members of the committee and replaced them with eight new members. It remains unclear how the new members of the panel will decide to approach recommendations for the RSV vaccine. As of Friday, the CDC director role remains vacant and Health and Human Services Secretary Robert F. Kennedy Jr. has been making final recommendations. In an April meeting, the prior advisory committee voted to recommend RSV vaccination for those aged 50 to 59 with increased risk of disease, but Kennedy did not adopt the recommendations. meeting scheduled to be held between June 25 and June 27 Moderna's RSV vaccine is based on mRNA technology, which some of the new members have expressed skepticism about, especially in relation to COVID-19 vaccines. Despite availability, RSV vaccination has been lagging. As of April 26, the latest date for which CDC data is available, an estimated 47.5% of adults aged 75 and older and 38.1% of adults aged 60 to 74 with a high-risk condition reported ever having received an RSV vaccine.
Yahoo
an hour ago
- Yahoo
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease. Previously, the vaccine, known as mRESVIA, had been licensed for use for those aged 60 and older. Approval for mRESVIA came after Moderna conducted a late-stage clinical trial showing the vaccine helped boost immune responses in younger adults. MORE: Despite 'game-changing' new RSV shots, uptake lagged among infants, adults: Experts More than one-third of adults between ages 18 and 59 have at least one underlying condition that puts them at increased risk of RSV, according to Moderna. "RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV," Stéphane Bancel, CEO of Moderna, said in a press release. "We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV." Although the FDA approves vaccines and may expand approvals for certain age groups, the Centers for Disease Control and Prevention sets recommendations regarding who should get vaccines and when. Currently, the CDC recommends RSV vaccination only for those aged 75 and older and for those aged 60 and over at increased risk. The CDC's independent vaccine advisory committee will need to vote to recommend that the new age group be eligible for the shot, followed by a final recommendation from the director of the CDC. Earlier this week, Kennedy removed all 17 sitting members of the committee and replaced them with eight new members. It remains unclear how the new members of the panel will decide to approach recommendations for the RSV vaccine. MORE: Respiratory virus activity remains 'high' in US and will 'continue for several more weeks': CDC As of Friday, the CDC director role remains vacant and Health and Human Services Secretary Robert F. Kennedy Jr. has been making final recommendations. In an April meeting, the prior advisory committee voted to recommend RSV vaccination for those aged 50 to 59 with increased risk of disease, but Kennedy did not adopt the recommendations. Instead, it appears Kennedy plans to have the new committee re-discuss the recommendations for RSV vaccination as well as discuss HPV and COVID vaccinations in their meeting scheduled to be held between June 25 and June 27 Moderna's RSV vaccine is based on mRNA technology, which some of the new members have expressed skepticism about, especially in relation to COVID-19 vaccines. Despite availability, RSV vaccination has been lagging. As of April 26, the latest date for which CDC data is available, an estimated 47.5% of adults aged 75 and older and 38.1% of adults aged 60 to 74 with a high-risk condition reported ever having received an RSV vaccine. FDA expands approval of Moderna's RSV vaccine to some adults under age 60 originally appeared on